The University of Chicago Header Logo

Connection

Michael Davidson to Clinical Trials as Topic

Back to Details
This is a "connection" page, showing publications Michael Davidson has written about Clinical Trials as Topic.
Michael Davidson
Connection Strength
1.735
Clinical Trials as Topic
  1. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 2006 Nov; 12(15 Suppl):S405-11.
    View in: PubMed
    Score: 0.170
  2. How I treat statin-associated side effects in an outpatient setting. Future Cardiol. 2021 10; 17(7):1249-1260.
    View in: PubMed
    Score: 0.114
  3. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. Clin Colorectal Cancer. 2018 09; 17(3):223-230.
    View in: PubMed
    Score: 0.095
  4. The future of n-3 polyunsaturated fatty acid therapy. Curr Opin Lipidol. 2016 12; 27(6):570-578.
    View in: PubMed
    Score: 0.086
  5. Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 2016 Mar; 246:121-9.
    View in: PubMed
    Score: 0.080
  6. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014 May; 126(3):56-65.
    View in: PubMed
    Score: 0.072
  7. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res. 2013 Feb; 54(2):467-72.
    View in: PubMed
    Score: 0.065
  8. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
    View in: PubMed
    Score: 0.061
  9. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol. 2011 Mar-Apr; 5(2):76-81.
    View in: PubMed
    Score: 0.057
  10. Update on CETP inhibition. J Clin Lipidol. 2010 Sep-Oct; 4(5):394-8.
    View in: PubMed
    Score: 0.055
  11. Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. J Clin Lipidol. 2010 Jan-Feb; 4(1):72-3; discussion 74.
    View in: PubMed
    Score: 0.053
  12. Focus on HDL as a therapeutic target for CAD risk reduction. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):1E-2E.
    View in: PubMed
    Score: 0.053
  13. Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):3E-9E.
    View in: PubMed
    Score: 0.053
  14. Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):52E-7E.
    View in: PubMed
    Score: 0.053
  15. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract. 2008 May; 57(5 Suppl High-Dose):S29-36.
    View in: PubMed
    Score: 0.047
  16. Global risk management in patients with type 2 diabetes mellitus. Am J Cardiol. 2007 Feb 19; 99(4A):41B-50B.
    View in: PubMed
    Score: 0.043
  17. Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
    View in: PubMed
    Score: 0.043
  18. Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec; 5(6):455-62.
    View in: PubMed
    Score: 0.040
  19. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol. 2005 Nov 07; 96(9A):59K-64K; discussion 34K-35K.
    View in: PubMed
    Score: 0.040
  20. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther. 2005 Sep; 3(5):789-820.
    View in: PubMed
    Score: 0.039
  21. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis. 2004 Sep-Oct; 47(2):73-104.
    View in: PubMed
    Score: 0.037
  22. Biologic therapies for dyslipidemia. Curr Atheroscler Rep. 2004 Jan; 6(1):69-72.
    View in: PubMed
    Score: 0.035
  23. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Curr Atheroscler Rep. 2003 Sep; 5(5):418-22.
    View in: PubMed
    Score: 0.034
  24. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Mar; 11(3):125-41.
    View in: PubMed
    Score: 0.031
  25. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002 Jan; 11(1):125-41.
    View in: PubMed
    Score: 0.030
  26. Statin trials in progress: unanswered questions. Curr Atheroscler Rep. 2001 Jan; 3(1):9-13.
    View in: PubMed
    Score: 0.028
  27. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs. 2001; 61(2):197-206.
    View in: PubMed
    Score: 0.028
  28. Long-term safety of risperidone. J Clin Psychiatry. 2001; 62 Suppl 21:26-8.
    View in: PubMed
    Score: 0.028
  29. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin Investig Drugs. 2000 Nov; 9(11):2663-71.
    View in: PubMed
    Score: 0.028
  30. Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. J Clin Lipidol. 2019 Nov - Dec; 13(6):997-1007.e8.
    View in: PubMed
    Score: 0.026
  31. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997 Jul 15; 42(2):138-43.
    View in: PubMed
    Score: 0.022
  32. Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). Schizophr Res. 2017 12; 190:74-76.
    View in: PubMed
    Score: 0.022
  33. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. Rev Cardiovasc Med. 2014; 15(1):1-10.
    View in: PubMed
    Score: 0.017
  34. The editor's roundtable: JUPITER follow-up. Am J Cardiol. 2011 May 15; 107(10):1549-57.
    View in: PubMed
    Score: 0.015
  35. Drugs in development for management of lipoprotein disorders. J Clin Lipidol. 2011 Mar-Apr; 5(2):66-75.
    View in: PubMed
    Score: 0.014
  36. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer Dis Assoc Disord. 1989; 3(4):224-7.
    View in: PubMed
    Score: 0.012
  37. Collaborative multidisciplinary workshop report: the role of epidemiology studies in determining a possible relationship between Chlamydia pneumoniae infection and atherothrombotic diseases. J Infect Dis. 2000 Jun; 181 Suppl 3:S430-1.
    View in: PubMed
    Score: 0.007
  38. Venous leg ulceration: evaluation of zinc treatment, serum zinc and rate of healing. Clin Exp Dermatol. 1977 Dec; 2(4):395-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.